A study on vaping behavior among Australian high school students has found those who reported severe depressive symptoms were over twice as likely to have tried e-cigarettes, compared to those reporting no depressive symptoms.
Marinus parts ways with 20% of its workforce – Pharmaceutical Technology
Oral ganaxolone, marketed under the brand name Ztalmy, first received FDA approval to treat seizures associated with CDKL5 deficiency disorder in March 2022. Credits: Tunatura/Shutterstock.com
May 9, 2024